You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed/refractory CLL

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Lymphocytic Leukemia(CLL), Small Lymphocytic Lymphoma Trial in Hackensack (Revlimid, Azacitidine)

Terminated
Has Results
  • Chronic Lymphocytic Leukemia(CLL)
  • Small Lymphocytic Lymphoma
  • Hackensack, New Jersey
    Hackensack University Medical Center
Jun 24, 2022

Chronic Lymphocytic Leukemia Trial in Lebanon (BNC105P, Ibrutinib)

Completed
  • Chronic Lymphocytic Leukemia
  • BNC105P
  • Ibrutinib
  • Lebanon, New Hampshire
    Dartmouth-Hitchcock Medical Center
Jan 3, 2023

Chronic Lymphocytic Leukemia Trial in Washington, Hackensack (Venetoclax, Rituximab, Rituximab/Hyaluronidase Human)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Washington, District of Columbia
  • +1 more
Mar 14, 2022

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

Chronic Lymphoid Leukemia Trial in Germany (Bendamustine, Obinutuzumab, Acalabrutinib)

Active, not recruiting
  • Chronic Lymphoid Leukemia
  • Dresden, Germany
  • +16 more
Nov 8, 2022

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • (no location specified)
Nov 9, 2023

Chronic Lymphocytic Leukemia, CLL, Relapsed CLL Trial (Dose combination 1-1, dose combination 1-2, Dose combination 1-3)

Withdrawn
  • Chronic Lymphocytic Leukemia
  • +8 more
  • Dose combination 1-1
  • +5 more
  • (no location specified)
Nov 1, 2021

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial run by the (Acalabrutinib (Arm A), Acalabrutinib (Arm B))

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Acalabrutinib (Arm A)
  • Acalabrutinib (Arm B)
  • Bethesda, Maryland
    Research Site
Jan 3, 2023

AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)

Recruiting
  • AML, Adult
  • CLL1 CAR-NK cell injection
  • Hangzhou, Zhejiang, China
    Clinical research ethics committee of the first affiliated hospi
Aug 30, 2023

Acute Myeloid Leukemia Trial in Beijing, Tianjin (LCAR-AMDR Cells Product)

Recruiting
  • Acute Myeloid Leukemia
  • LCAR-AMDR Cells Product
  • Beijing, Beijing, China
  • +1 more
Jan 28, 2023

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma Trial (Nemtabrutinib, Venetoclax,

Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +5 more
  • (no location specified)
Jul 21, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia Trial in Boston (Acalabrutinib,

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 19, 2022

Acute Myeloid Leukemia Trial in Kunming (CLL1 and CD38 dual-target CAR-T injection)

Recruiting
  • Acute Myeloid Leukemia
  • CLL1 and CD38 dual-target CAR-T injection
  • Kunming, Yunnan, China
    920th Hospital of Joint LogisticsSupport Force of People's Liber
Oct 26, 2023

CLL/SLL Trial in Worldwide (Epcoritamab, Venetoclax)

Not yet recruiting
  • CLL/SLL
  • Antwerpen, Belgium
  • +23 more
Mar 28, 2023

Chronic Lymphocytic Leukemia (CLL) Trial in Boston (Ibrutinib, Copanlisib, Acalabrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
May 13, 2022

Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • +6 more
  • Beijing, China
    Beijing Cancer Hospital
Feb 6, 2023

Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Trial in Chicago, Rochester, Cleveland (Venetoclax, Umbralisib, Ublituximab)

Terminated
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma
  • Chicago, Illinois
  • +2 more
Aug 19, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL) Trial in Switzerland, United

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +6 more
  • Tucson, Arizona
  • +23 more
Dec 14, 2021

B-cell NHL, CLL Trial (CARCIK-CD19)

Not yet recruiting
  • B-cell NHL
  • CLL
  • CARCIK-CD19
  • (no location specified)
May 19, 2023

AML Trial in Hangzhou (CLL1 CAR-T)

Not yet recruiting
  • AML
  • CLL1 CAR-T
  • Hangzhou, China
    The First Affiliated Hospital, Zhejiang University
Jul 17, 2022

AML Trial in Hangzhou (CLL1+CD33 CAR-T)

Not yet recruiting
  • AML
  • CLL1+CD33 CAR-T
  • Hangzhou, China
    Mingming Zhang Zhang
Jul 19, 2022

Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory Trial in Orange,

Recruiting
  • Follicular B-cell Non-Hodgkin's Lymphoma
  • +7 more
  • MB-106
  • Orange, California
  • +3 more
Nov 1, 2022

CLL Trial in Stony Brook, Oklahoma City (Zandelisib, Rituximab, Venetoclax)

Recruiting
  • CLL
  • Stony Brook, New York
  • +1 more
May 12, 2022

Multiple Myeloma (MM), DLBCL, Not Otherwise Specified, Double Hit Lymphoma Trial in Spain (IDP-121)

Recruiting
  • Multiple Myeloma (MM)
  • +5 more
  • Santander, Cantabria, Spain
  • +4 more
Jun 19, 2023

Chronic Lymphocytic Leukemia Trial in Milano (Venetoclax, Imbruvica Oral Product)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Milano, MI, Italy
    Ospedale San Raffaele
Apr 2, 2022